BRAF and neoplasm: Better characterization, classification and profiling of therapy-induced tumor evolution should yield therapeutic options that incorporate knowledge of cancer cell and tumor microenvironment cell factors to preclude or constrain tumor evolution during initial treatment and transform BRAF-mutant cancers into chronic or curable conditions.